Chief Executive Officer
Sol is an inventor and entrepreneur with over 20 years experience in biomedical research and product development. He is also an Associate Professor of Engineering at Dartmouth where he is a Member of the Translational Engineering in Cancer Research Program at the Dartmouth-Hitchcock Medical Center. Sol has over 50 publications, 2500 citations, and holds 8 US patents.
Director of Immunology
Arti is Lodestone's subject matter expert in cancer biology, immunology, biomarkers, and implantable biosensors. She is also an Assistant Professor of Neurology at Geisel School of Medicine at Dartmouth where she is the Study Chair and PI on a multi-institutional clinical trial on cancer biomarkers. Arti directed all of Lodestone’s preclinical studies at the Dartmouth-Hitchcock Medical Center.
Director of Nanotechnology
Hye Jung is an experienced chemist who specializes in organic and polymer synthesis, analytical chemistry, and biomaterials development. She excels in innovative process and product development. Hye Jung is responsible for the design, development and validation of functionalized magnetic nanoparticles at Lodestone.
Mechanical Engineer
Seth is a mechanical engineer with a experience in the design of industrial fluid and mechanical systems. He completed his Master of Engineering degree at the Thayer School of Engineering at Dartmouth. Seth is responsible for the development of Lodestone's magnetic nanoparticle reader platforms and is currently developing a next generation preclinical system.
Biomedical Engineer
Carmen is a dedicated researcher with extensive experience in designing and running preclinical experiments. At Lodestone he is responsible for implant design, miniaturization, and optimization. Currently Carmen is designing an automated production system for sterile assembly and validation testing of IRIS biosensors.
Scientific Advisor
Christian is a biomedical engineer and co-inventor of Lodestone’s IRIS biosensor. He completed his PhD at the Physikalisch-Technische Bundesanstalt in Berlin, Germany focusing on the topic of quantitative detection of magnetic nanoparticles in biological samples.
Strategic Advisor
John is the CFO and co-founder of S1 Biopharma, a developer of prescription therapeutics for under-treated CNS dysfunctions. Prior to that, John was a finance executive at Laureate Education and Fidelity Investments, where he had senior finance and FP&A roles overseeing multinational high-growth operating subsidiaries.
Strategic Advisor
Rick is an entrepreneur and biomedical engineer with over 25 years of medical device commercialization experience. He is the founder and CEO of Simbex (Lebanon, NH), and was founding CEO of venture-funded iWalk (now BionX). He is a Fellow of the National Academy of Inventors, and holds 15 US patents, with 4 pending.
Human Resources Advisor
Throughout his forty-five-year career, Roland has developed a strong reputation as an internationally-respected Talent Development expert. He has led Human Resources globally in multiple sectors for global companies of varying complexity, and has successfully coached CEOs, Presidents, General Managers, and other business leaders from twenty countries.
In 2015 Sol Diamond, Lidia Valdés and Brad Ficko set out to revolutionize medical diagnostics and founded Lodestone Biomedical out of a basement laboratory at Dartmouth College. Early on Lodestone aimed to bring low-cost, high-sensitivity magnetic detection methods into the medical device market. Our goal was not to incrementally improve existing diagnostics, but to measure what was previously impossible to detect. In close collaboration with advisors and clinical collaborators, we refined our magnetic detection methods over the years to the biosensing and monitoring system we offer today.
A naturally occurring magnetic rock composed of the mineral magnetite.
In ancient times, explorers used lodestones to make magnetic compasses for navigation on land and at sea. This extraordinary history of magnetite is reflected in the name "Lodestone", which means "leading stone.”
Today magnetite forms the core of Lodestone Biomedical's magnetic nanoparticle platform technology for in vivo biomarker monitoring in immuno-oncology. Our biosensors serve as a "molecular compass" for cancer immunotherapy drug development from bench to bedside.
Learn more about the history of the magnetic mineral on the website of the National High Magnetic Field Laboratory.
Lodestone's products and services are for research use only. Leverage our unique technical solutions in your preclinical studies.
Request a Consultation
